This means that passive immunization with tau antibodies is often a feasible therapeutic goal and which the CSF volume of p-tau262/356 or of the microtubule binding area (MTBD) can serve as a handy biomarker of tau pathology to watch tau therapeutics in clinical trials.Immerse yourself in TAU’s bold and emotionally charged functions, where cubist